Mold-Tek Technologies Projects 20%+ EBITDA Margin And 20-25% Revenue Growth CAGR
Mold-Tek Technologies has announced a multi-year financial roadmap targeting 20–25% revenue CAGR alongside 20%+ EBITDA margins and 15–16% PAT margins across FY27–28.
Market snapshot: Mold-Tek Technologies Limited has outlined its medium-term financial targets, setting an EBITDA margin outlook of 20%+ and a PAT margin target of 15% to 16%. The company aims to sustain a revenue growth CAGR of 20% to 25% across FY27 and FY28.
Data Snapshot
- EBITDA Margin Outlook: Target set at 20%+ for FY27-28.
- PAT Margin Guidance: Target established at 15% to 16% for FY27-28.
- Revenue Growth Trajectory: Target set at 20% to 25% CAGR for FY27-28.
- Q2 FY27 Consolidated Revenue: Reported at ₹60.81 crore, representing a 51.2% YoY growth.
- Q2 FY27 Consolidated Net Profit: Reported at ₹9.62 crore, reflecting a 197.32% YoY rise.
What's Changed
- Q2 FY27 revenue grew 51.2% YoY to ₹60.81 crore, up from ₹40.22 crore in Q2 FY26.
- Q2 FY27 net profit reached ₹9.62 crore, marking a 197.32% YoY growth over the prior-year period.
Key Takeaways
- Target EBITDA margin of 20%+ signals operating efficiency in high-value engineering design services.
- PAT margin outlook of 15–16% demonstrates net profitability conversion over FY27–28.
- Revenue growth target of 20–25% CAGR reflects ongoing expansion in civil, structural, and mechanical engineering order pipelines.
SAHI Perspective
Mold-Tek Technologies' medium-term guidance is anchored by recent performance in Q2 FY27, where revenue surged to ₹60.81 crore and net profit rose to ₹9.62 crore. The target EBITDA margin of 20%+ reflects management's focus on high-margin structural engineering offerings.
Market Implications
Achieving a 20-25% CAGR alongside 20%+ EBITDA margins places Mold-Tek Technologies favorably among engineering services small-caps. Continued quarterly operational execution will be essential to sustain market sentiment.
Trading Signals
Market Bias: Bullish
Supported by strong Q2 FY27 results where revenue grew 51.2% YoY to ₹60.81 crore and net profit reached ₹9.62 crore, alongside robust medium-term margin targets of 20%+ EBITDA.
Overweight: Engineering Services, Civil & Structural Engineering Design
Trigger Factors:
- Quarterly top-line tracking against the 20-25% CAGR benchmark
- EBITDA margin sustaining above the 20% floor
- Order inflows across primary structural engineering domains
Time Horizon: Medium-term (3-12 months)
Industry Context
Engineering services firms in India benefit from steady demand in structural design and mechanical services. Companies expanding high-value consultancy services typically achieve operating margins around 20%.
Key Risks to Watch
- Slower order intake in export engineering markets
- Talent retention costs impacting net profit margin targets of 15-16%
- Macroeconomic softness delaying client capital expenditure projects
Recent Developments
On November 4, 2026, Mold-Tek Technologies reported record Q2 FY27 consolidated revenue of ₹60.81 crore (+51.2% YoY) and net profit of ₹9.62 crore (+197.32% YoY), alongside EBITDA of ₹14.58 crore (+144.5% YoY).
Closing Insight
Mold-Tek Technologies exhibits a clear medium-term outlook supported by structural demand and expanding operating margins.
High Performance Trading with SAHI.
Disclaimer: This news section may include AI-generated or AI-assisted news, summaries, drafts, or insights. All content is subject to human review before publication. While we aim for accuracy, readers should independently verify information before relying on it.
Open Free AccountRelated
Refex Industries Secures Two-Year Pond Ash Contract Worth ₹28 Crore
Easy Trip Planners Launches 'Raahi' AI WhatsApp Chatbot For Social Travel
Caplin Point Laboratories Faces US FDA OAI Classification For Caplin Steriles Facility With 10 Observations
AstraZeneca Pharma India Partners With Strand Life Sciences For Healthcare Collaboration
Recent
Refex Industries Secures Two-Year Pond Ash Contract Worth ₹28 Crore
Easy Trip Planners Launches 'Raahi' AI WhatsApp Chatbot For Social Travel
Caplin Point Laboratories Faces US FDA OAI Classification For Caplin Steriles Facility With 10 Observations
AstraZeneca Pharma India Partners With Strand Life Sciences For Healthcare Collaboration
Frequently Asked Questions (FAQs)
All topics
Click the link, confirm the box next to sahi.com is checked — ignore any other results.